R&D | October 28, 2025
MilliporeSigma partners with Promega to advance 3-D cell drug discovery technologies
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
The event will be attended by 35,000+ industry professionals
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Subscribe To Our Newsletter & Stay Updated
